Nanochap’s V-BCI directly implants a Flexible Electrode Array into the visual cortex, bypassing the retina and optic nerve pathways to directly stimulate neurons in the visual cortex and thereby enable artificial visual perception. V-BCI is designed for patients with blindness who have undergone eye removal or have severe optic nerve atrophy, optic nerve transection, or congenital absence of the optic nerve. The V-BCI product has entered animal trials, with First-in-Human (FIH) trial planned to begin in 2026.